Petros

Spectrum CEO to Deliver Testimony to Senate HELP Committee

Retrieved on: 
Tuesday, March 22, 2022
Hearing, University of Washington, Retirement, Compliance, SEC, Spectrum, Arizona State University, Topical steroid withdrawal, Labour, Documentation, Petros, Committee, COVID-19, GLOBE, Solution, United States Senate Committee on Commerce, Science, and Transportation, Education, University, Financial adviser, Pension fund, Health, State, Pension

TACOMA, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Spectrum Pension Consultants, Inc. (Spectrum) today announced its Managing Director and Chief Executive Officer, Petros Koumantaros (Petros) will deliver testimony before a hearing of the United States Senate Committee on Health, Education, Labor, and Pensions (the Committee) in support of retirement security.

Key Points: 
  • TACOMA, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Spectrum Pension Consultants, Inc. (Spectrum) today announced its Managing Director and Chief Executive Officer, Petros Koumantaros (Petros) will deliver testimony before a hearing of the United States Senate Committee on Health, Education, Labor, and Pensions (the Committee) in support of retirement security.
  • Petros joined Spectrum, the firm founded by Petross father, over 16 years ago.
  • I thank Chair Patty Murray, Ranking Member Richard Burr, and all the Committee members for the invitation to provide testimony.
  • More information about the Committee, GROUPIRA, intellicents, and Spectrum is available at: http://help.senate.gov , http://GROUPIRA.com , http://intellicents.com , and http://spectrumpension.com .

Aries I Acquisition Corporation Announces Board Change

Retrieved on: 
Thursday, July 22, 2021
Professional services, Finance, Fictional characters, Astronomy, Comics, Aries, Ram, Petros, NASDAQ

Aries I Acquisition Corporation (Nasdaq: RAM) (Nasdaq: RAMMU) ("Aries" or the "Company") announced that Petros Kitsos has resigned as a member of the Board of Directors of the Company in order to concentrate his efforts on building his family office.

Key Points: 
  • Aries I Acquisition Corporation (Nasdaq: RAM) (Nasdaq: RAMMU) ("Aries" or the "Company") announced that Petros Kitsos has resigned as a member of the Board of Directors of the Company in order to concentrate his efforts on building his family office.
  • Mr. Kitsos will continue to serve Aries in an advisory role.
  • Aries CEO Randy Brinkley commented: "Petros has been a valued member of the Aries Board and we would like to express our sincere gratitude for his hard work and significant contributions in that role.
  • Aries I Acquisition Corporation was founded by its Chairman, Thane Ritchie.

Petros Pharmaceuticals Establishes Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil)

Retrieved on: 
Thursday, February 4, 2021
Petros, Forward-looking statement

We are looking forward to exploring the possibilities available to facilitate access to Stendra while differentiating it in the market.

Key Points: 
  • We are looking forward to exploring the possibilities available to facilitate access to Stendra while differentiating it in the market.
  • The Company recently undertook a relaunch of Stendra, generating gross revenues of approximately$30 millionin 2019.
  • Petros intends to accelerate the relaunch of Stendrawith a well-funded commercial organization and refocused strategy.
  • These forward-looking statements are based upon Petros Pharmaceuticals, Inc.'s ("Petros," "we," "our," "us" or the "Company") management's assumptions, expectations, projections, intentions and beliefs about future events.

Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals

Retrieved on: 
Wednesday, December 2, 2020
Corporate finance, Human resource management, Mergers and acquisitions, Petros, Metuchen, New Jersey

In connection with the completed merger and pursuant to the terms of the Merger Agreement, Neurotrope and Metuchen have merged in an all-stock transaction forming a newly traded holding company named Petros Pharmaceuticals, Inc. ("Petros").

Key Points: 
  • In connection with the completed merger and pursuant to the terms of the Merger Agreement, Neurotrope and Metuchen have merged in an all-stock transaction forming a newly traded holding company named Petros Pharmaceuticals, Inc. ("Petros").
  • Pursuant to the terms of the Merger Agreement, Metuchen shareholders also may receive additional shares of Petros common stock issuable upon the achievement of certain milestones.
  • Petros will be led by Fady Boctor, Chief Commercial Officer of Metuchen, who has been named President and CCO.
  • "The closing of this merger transaction marks the beginning of a new chapter for Petros," said Mr. Boctor.

Petros PACE Finance Welcomes Michael Yaki as SVP and Senior Counsel - Policy and Programs

Retrieved on: 
Wednesday, November 11, 2020
Energy sources, Alternative energy, Renewable energy policy, PACE financing, Renewable energy in the United States, Solar energy in the United States, Energy, Petros, Michael Yaki

AUSTIN, Texas, Nov. 11, 2020 /PRNewswire/ -- Petros PACE Finance, ( www.petros-pace.com ), the industry leader of Commercial PACE financing, announced that Michael Yaki has joined the company as Senior Vice President and Senior Counsel of Policy and Programs.

Key Points: 
  • AUSTIN, Texas, Nov. 11, 2020 /PRNewswire/ -- Petros PACE Finance, ( www.petros-pace.com ), the industry leader of Commercial PACE financing, announced that Michael Yaki has joined the company as Senior Vice President and Senior Counsel of Policy and Programs.
  • In his new position, Mr. Yaki will engage in the establishment and maintenance of C-PACE programs across the country.
  • "Michael's policy background plus his experience with C-PACE programs will be an extremely beneficial add to Petros, as we navigate the growth in the market," said Mansoor Ghori, CEO and Co-founder at Petros PACE Finance.
  • For years, Mr. Yaki's law and policy expertise has driven new market creation and PACE innovation across the country.

Petros PACE Finance's Growth Continues with Hiring of Commercial Real Estate Executive Jerry Ellis as Senior Vice President of Business Development

Retrieved on: 
Tuesday, October 13, 2020
Energy sources, Alternative energy, Renewable energy policy, PACE financing, Renewable energy in the United States, Solar energy in the United States, Petros, PACE, Energy

AUSTIN, Texas, Oct. 13, 2020 /PRNewswire/ --Petros PACE Finance,( www.petros-pace.com ), the industry leader of Commercial PACE financing, announced today the hiring ofJerry Ellis as Senior Vice President of Business Development based in theNew York office, strengthening the business development team as the company continues to grow nationally.

Key Points: 
  • AUSTIN, Texas, Oct. 13, 2020 /PRNewswire/ --Petros PACE Finance,( www.petros-pace.com ), the industry leader of Commercial PACE financing, announced today the hiring ofJerry Ellis as Senior Vice President of Business Development based in theNew York office, strengthening the business development team as the company continues to grow nationally.
  • Ellis brings more than 25 years of commercial real estate investing experience to the role.
  • "New York is an increasingly important market for Petros, where we are expanding to meet rapidly growing demand for C-PACE," saidMansoor Ghori, CEO and Co-founder at Petros PACE Finance.
  • "Petros is on the leading edge of an industry with tremendous opportunity for growth and sustainable impact," said Ellis.

Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen

Retrieved on: 
Wednesday, September 30, 2020
Corporate finance, Human resource management, Mergers and acquisitions, Petros

Neurotrope and Metuchen previously announced their intent to merge in an all-stock transaction resulting to form a NASDAQ-traded holding company to be named Petros Pharmaceuticals, Inc. ("Petros").

Key Points: 
  • Neurotrope and Metuchen previously announced their intent to merge in an all-stock transaction resulting to form a NASDAQ-traded holding company to be named Petros Pharmaceuticals, Inc. ("Petros").
  • As part of the Amended Merger Agreement, Neurotrope shareholders currently representing 34% of the Company's outstanding shares have signed a shareholder rights agreement in support of the merger.
  • Petros will be led by Fady Boctor, Chief Commercial Officer of Metuchen, who will be named President and CCO.
  • These forward-looking statements include statements regarding Petros, Neurotrope, Metuchen, the combined company, the proposed transaction and other matters.

Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company

Retrieved on: 
Monday, May 18, 2020
Corporate finance, Human resource management, Mergers and acquisitions, Petros, Economy, Business, Humans

The merger is expected to close during the third quarter of 2020, subject to customary closing conditions, including approval of the merger agreement by the shareholders of Neurotrope.

Key Points: 
  • The merger is expected to close during the third quarter of 2020, subject to customary closing conditions, including approval of the merger agreement by the shareholders of Neurotrope.
  • Charles S. Ryan, J.D., Ph.D., Chief Executive Officer of Neurotrope, will be President, Chief Executive Officer and a Director of Petros.
  • "We are delighted to offer our investors an investment in two companies, Petros Pharmaceuticals, Inc. and the spin-out company Neurotrope Bioscience, Inc.," said Mr. Silverman.
  • These forward-looking statements include statements regarding Petros, Neurotrope, Metuchen, the combined company, the proposed transaction and other matters.

Petros PACE Finance Provides $9.9 million in C-PACE Financing for Restoration of Historic Hotel in Syracuse, New York

Retrieved on: 
Monday, February 24, 2020
Marriott International, Petros, Marriott Syracuse Downtown, Humans

The 261-key hotel opened in 2016 following a historical restoration of the 1920s-era building formerly known as Hotel Syracuse.

Key Points: 
  • The 261-key hotel opened in 2016 following a historical restoration of the 1920s-era building formerly known as Hotel Syracuse.
  • Further renovations, expected to complete in May 2020, will add 50 rooms, along with additional function space and a restaurant.
  • "This is the first C-PACE project Petros has funded in New York, marking the second new market we've expanded into so far in 2020," said Mansoor Ghori, Co-Founder and CEO of Petros PACE Finance.
  • To learn more about Petros PACE Finance visit our website at www.petros-pace.com/ .

Petros PACE Finance Provides $4.2 million in C-PACE Financing for Conversion of Historic Logan Building into Boutique Hotel

Retrieved on: 
Wednesday, January 29, 2020
Omaha, Nebraska, Petros, Indigo Books and Music

The transaction will fund a portion of the renovation of Omaha's century-old Logan Building.

Key Points: 
  • The transaction will fund a portion of the renovation of Omaha's century-old Logan Building.
  • The 7-story building will be operated as a 90-key Hotel Indigo, with additional space for condos and ground-level retail that also includes a restaurant and speakeasy.
  • "C-PACE has now become an indispensable development tool for historic rehabilitation projects, as a low-cost, long-term financing option that also promotes sustainability," said Mansoor Ghori, Petros PACE Finance CEO.
  • To learn more about Petros PACE Finance visit our website at www.petros-pace.com/ .